Inclusion Criteria

Criteria:

- Histologically or cytologically confirmed pancreatic adenocarcinoma OR other solid
tumor:

- Not amenable to curative therapy

- Previously untreated metastatic pancreatic adenocarcinoma allowed

- Measurable or evaluable disease

- No history of or known brain metastases, spinal cord compression, carcinomatous
meningitis, or new evidence of brain or leptomeningeal disease on screening CT scan
or MRI scan

- ECOG performance status (PS) 0-2 OR Karnofsky PS 60-100%

- Life expectancy >= 12 weeks

- Absolute neutrophil count >= 1,500/mm3

- Platelet count >= 100,000/mm3

- Hemoglobin >= 8.5 g/dL

- Bilirubin =< 1.5 mg/dL

- Creatinine normal OR creatinine clearance >= 60 mL/min

- AST and ALT =< 2.5 times upper limit of normal (ULN) (=< 5 times ULN if due to
underlying disease)

- Calcium =< 12.0 mg/dL

- Not pregnant or nursing

- Negative pregnancy test

- Fertile patients must use effective contraception during and for at least 6 months
after completion of study therapy

- LVEF normal by MUGA scan or ECHO at baseline

- Deep venous thrombosis or pulmonary embolism allowed provided they are clinically
stable and adequately treated

- No preexisting thyroid abnormality that results in the inability to maintain thyroid
function in the normal range while using medication

- No history of allergic reactions attributed to compounds of similar chemical or
biological composition to sunitinib malate

- No history of any of the following within the past 6 months:

- Myocardial infarction

- Ventricular arrhythmia (i.e., ventricular tachycardia or ventricular
fibrillation >= 3 beats in a row)

- Severe/unstable angina

- Severe peripheral vascular disease (i.e., claudication)

- Procedure on peripheral vasculature

- Coronary/peripheral artery bypass graft

- Cerebrovascular accident

- No history of any of the following within the past 6 months:

- Transient ischemic attack;

- Clinically significant bleeding requiring red blood cell transfusion

- No NYHA class III or IV heart disease:

- Patients with NYHA class II disease who are stable and on medication are
eligible

- No ongoing cardiac dysrhythmias >= grade 2, atrial fibrillation of any grade, or any
significant EKG abnormalities

- No hypertension that cannot be controlled by medications to a systolic blood pressure
(BP) of < 140 mm Hg and diastolic BP of < 90 mm Hg

- No condition that impairs the ability to swallow and retain sunitinib malate tablets,
including any of the following:

- Gastrointestinal tract disease resulting in an inability to take oral medication

- Requirement for IV alimentation

- Prior surgical procedures affecting absorption

- Active peptic ulcer disease

- No gastrointestinal perforation or intra-abdominal abscess within the past 28 days

- No serious nonhealing infection or bone fracture

- No other severe acute or chronic medical condition, psychiatric condition, or
laboratory abnormality that would preclude study therapy

- May have received any number of prior systemic therapies

- More than 4 weeks since prior radiotherapy or surgery and recovered

- More than 4 weeks since other prior therapies and recovered

- Prior gemcitabine hydrochloride allowed

- No prior sunitinib malate or other therapy directed against VEGF, including any of
the following:

Sorafenib; Bevacizumab; Vatalanib; AZD2171; VEGF Trap; Investigational antiangiogenic
therapy

- More than 7 days since prior and no concurrent CYP3A4 inhibitors, including any of
the following:

- Ketoconazole

- Itraconazole

- Clarithromycin

- Erythromycin

- Diltiazem

- Verapamil

- Indinavir

- Ritonavir

- Nelfinavir

- Saquinavir

- Atazanavir

- Delavirdine

- More than 12 days since prior and no concurrent CYP3A4 inducers, including any of the
following:

- Rifampin

- Rifabutin

- Carbamazepine

- Phenobarbital

- Phenytoin

- Hypericum perforatum (St. John's wort)

- Efavirenz

- Tipranavir

- No concurrent agents with proarrhythmic potential, including any of the following:

- Terfenadine

- Quinidine

- Procainamide

- Disopyramide

- Sotalol

- Probucol

- Bepridil

- Haloperidol

- Risperidone

- Indapamide

- Flecainide

- No concurrent combination antiretroviral therapy for HIV-positive patients

- No concurrent treatment on another clinical trial:

Participation in non-therapeutic clinical trials allowed

- QTc < 500 msec